Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1143)	12/8/1998 6:15:00 PM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

Peter, Thanks for the three abstracts, but I'm a little confused by your assessment of them. As I read them, the first abstract indicated that a decrease of PSA of 50% or more (though in only eight weeks in that study) was associated with a significantly increased survival. The second abstract indicated “limited activity” with what seems to be a rather brutal regimen of topotecan. The third abstract involved pancreatic cancer under a topotecan dosing regimen which provided no benefit. The fact that there was no response in the pancreatic trial seems to simply emphasize the need for a better treatment for that cancer. Let's hope that MGI 114 is the answer for that cancer. Please correct me if I missed something. Until then, I'm still overly –enthusiastic. :-) David